<h4>Background</h4>Brain metastasis is the most common form of tumor recurrence after resistance to crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). This evidence concerns the gene ALK and non-small cell lung carcinoma.